HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer

Cell Death and Disease

Volumn 5, Issue 1, 2014, Pages

  Schulz, R ^a   Streller, F ^a   Scheel, A H ^b   Ruschoff J ^b   Reinert, M C ^a   Dobbelstein, M ^a   Marchenko, N D ^c   Moll, U M ^a,c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Institute for Pathology Nordhessen   (Germany)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

ErbB2; HSF1; HSP90; MIF; mTOR; HER2

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CHAPERONE; CP 274714; CP 724714; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MIGRATION INHIBITION FACTOR; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE ACTIVATION; GENE CONTROL; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HEAT STRESS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; MICE, KNOCKOUT; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS;

EID: 84891756044     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.508     Document Type: Article

References (60)

1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
2. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 1987; 84: 7159-7163.
3. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987; 237: 178-182.
4. Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007; 7: 389-397.
5. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012; 12: 553-563.
6. Nahta R. Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol 2012; 2012: 428062.
7. Schulz R, Marchenko N, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L et al. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med 2012; 209: 275-289.
8. Bucala R, Donnelly SC. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 2007; 26: 281-285.
9. Conroy H, Mawhinney L, Donnelly SC. Inflammation and cancer: macrophage migration inhibitory factor (MIF) - the potential missing link. Q J Med 2010; 103: 831-836.
10. Nemajerova A, Moll UM, Petrenko O, Fingerle-Rowson G. Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle 2007; 6: 1030-1034.
11. Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N et al. Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res 2002; 93: 389-396.
12. Bini L, Magi B, Marzocchi B, Arcuri F, Tripodi S, Cintorino M et al. Protein expression profiles in human breast ductal carcinoma and histologically normal tissue. Electrophoresis 1997; 18: 2832-2841.
13. Cheng RJ, Deng WG, Niu CB, Li YY, Fu Y. Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma. Int J Gynecol Cancer 2011; 21: 1004-1012.
14. Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N et al. Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. Anticancer Res 2010; 30: 3313-3319.
15. Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression and angiogenesis. Mol Cancer Ther 2007; 6: 1993-2002.
16. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005; 175: 1197-1205.
17. He XX, Yang J, Ding YW, Liu W, Shen QY. Xia HHX. Increased epithelial and serum expression of macrophage migartion inhibitory factor (MIF) in gastric cancer carcinogenesis. Gut 2006; 55: 797-802.
18. Hira E, Ono T, Dhar DK, El-Assal ON, Hishikawa Y, Yamanoi A et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma. Cancer 2005; 103: 588-598.
19. Meyer-Siegler KL. Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells. J Inter Cytokine Res 2000; 20: 769-778.
20. Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R, Vera PL. Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol 2006; 177: 8730-8739.
21. Pyle ME, Korbonits M, Gueorguiev M, Jordan S, Kola B, Morris DG et al. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J Endocrinol 2003; 176: 103-110.
22. Reome JB, Hylind JC, Dutton RW, Dobrzanski MJ. Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer. Clin Immunol 2004; 111: 69-81.
23. Tomiyasu M, Yoshino I, Suemitsu R, Okamoto T, Sugimachi K. Quantification of Macrophage migration inhibitory factor mRNA expression in non-small cell lung cancer tissues and its clinical signficance. Clin Cancer Res 2002; 8: 3755-3760.
24. Verjans E, Noetzel E, Bektas N, Schütz AK, Lue H, Lennartz B et al. Dual role of macrophage migration inhibitory factor (MIF) in human breast cancer. BMC Cancer 2009; 9: 1-18.
25. Wang XB, Tian XY, Li Y, Li B, Li Z. Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas. J Neurooncol 2012; 106: 43-51.
26. Xu X, Wang B, Ye C, Yao C, Lin Y, Huang X et al. Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer. Cancer Lett 2008; 261: 147-157.
27. Zhou S, Xu S, Zhang H, Liu Z, Liang Z, Song X et al. [Prognostic significance of angiogenesis and blood vessel invasion in stage I non-small cell lung cancer after complete surgical resection]. Zhongguo Fei Ai Za Zhi 2007; 10: 29-33.
28. Petrenko O, Moll UM. Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell 2005; 17: 225-236.
29. Talos F, Mena P, Fingerle-Rowson G, Moll UM, Petrenko O. MIF loss impairs Myc-induced lymphomagenesis. Cell Death Differ 2005; 12: 1319-1328.
30. Martin J, Duncan FJ, Keiser T, Shin S, Kusewitt DF, Oberyszyn T et al. Macrophage migration inhibitory factor (MIF) plays a critical role in pathogenesis of ultraviolet-B (UVB)-induced nonmelanoma skin cancer (NMSC). FASEB J 2009; 23: 720-730.
31. Wilson JM, Coletta PL, Cuthbert RJ, Scott N, MacLennan K, Hawcroft G et al. Macrophage migration inhibitory factor promotes intestinal tumorigenesis. Gastroenterology 2005; 129: 1485-1503.
32. Taylor JA, Kuchel GA, Hedge P, Voznesensky OS, Claffey K, Tsimikas J et al. Null mutation for macrophage migration inhibitory factor (MIF) is associated with less agressive bladder cancer in mice. BMC Cancer 2007; 7: 1-8.
33. Choi J, Jung WH, Koo JS. Metabolism-related proteins are differentially expressed according to the molecular subtype of invasive breast cancer defined by surrogate immunohistochemistry. PathobiolJ Immunopathol Mol Cell Biol 2013; 80: 41-52.
34. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nature reviews. Cancer 2005; 5: 761-772.
35. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010; 11: 515-528.
36. Trepel J, Mollarpour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev 2010; 10: 537-549.
37. Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldamycin. J. Biol Chem 1996; 271: 22796-22801.
38. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. JBC 2002; 227: 39858-39866.
39. Schulte TW, Blagosklonny MV, Ingui C, Neckers L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995; 270: 24585-24588.
40. Li D, Marchenko ND, Schulz R, Fisher V, Velasco-Hernandez T, Talos F et al. Functional inactivation of endogenous MDM2 and CHIP by Hsp90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res 2011; 9: 577-588.
41. Ali A, Bharadwaj S, O'Carroll R, Ovsenek N. HSP90 interacts with and regulates the activity of heat shock factor 1 in Xenopus oocytes. Mol Cell Biol 1998; 18: 4949-4960.
42. Santagata S, Hu R, Lin NU, Mendillo ML, Collins LC, Hankinson SE et al. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc Natl Acad Sci USA 2011; 108: 18378-18383.
43. Dai C, Whitesell L, Rogers AB, Lindquist S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007; 130: 1005-1018.
44. Meng L, Gabai VL, Sherman MY. Heat-shock transcription factor HSF1 has a critical role in human epidermal growth factor receptor-2-induced cellular transformation and tumorigenesis. Oncogene 2010; 29: 5204-5213.
45. Xi C, Hu Y, Buckhaults P, Moskophidis D, Mivechi NF. Heat shock factor Hsf1 cooperates with ErbB2 (Her2/Neu) protein to promote mammary tumorigenesis and metastasis. J Biol Chem 2012; 287: 35646-35657.
46. Dai C, Santagata S, Tang Z, Shi J, Cao J, Kwon H et al. Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis. J Clin Invest 2012; 122: 3742-3754.
47. Mendillo ML, Santagata S, Koeva M, Bell GW, Hu R, Tamimi RM et al. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell 2012; 150: 549-562.
48. Calderwood SK, Gong J. Molecular chaperones in mammary cancer growth and breast tumor therapy. J Cell Biochem 2012; 113: 1096-1103.
49. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D et al. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 2009; 28: 3689-3701.
50. Guettouche T, Boellmann F, Lane WS, Voellmy R. Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress. BMC Biochem 2005; 6: 4.
51. Chou SD, Prince T, Gong J, Calderwood SK. mTOR is essential for the proteotoxic stress response, HSF1 activation and heat shock protein synthesis. PLoS One 2012; 7: e39679.
52. Khaleque MA, Bharti A, Sawyer D, Gong J, Benjamin IJ, Stevenson MA et al. Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorageindependent growth. Oncogene 2005; 24: 6564-6573.
53. Bijur GN, Jope RS. Opposing actions of phosphatidylinositol 3-kinase and glycogen synthase kinase-3beta in the regulation of HSF-1 activity. J Neorochem 2000; 75: 2401-2408.
54. Chu B, Soncin F, Price BD, Stevenson MA, Calderwood SK. Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 represses transcriptional activation by heat shock factor-1. J Biol Chem 1996; 271: 30847-30857.
55. He B, Meng YH, Mivechi NF. Glycogen synthase kinase 3beta and extracellular signal-regulated kinase inactivate heat shock transcription factor 1 by facilitating the disappearance of transcriptionally active granules after heat shock. Mol Cell Biol 1998; 18: 6624-6633.
56. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008; 3: e3065.
57. Zhang C, Liang T, Song J, Jiang S, Qu L, Hou G. Evaluation of macrophage migration inhibitory factor as an imaging marker for hepatocellular carcinoma in murine models. Scand J Gastroenterol 2011; 46: 720-726.
58. Schulz R, Dobbelstein M, Moll UM. HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates. Oncoimmunology 2012; 1: 1425-1426.
59. Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol 1998; 18: 85-92.
60. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000; 19: 968-988.